Pelago Bioscience today announced the company has entered into a technology access program and license agreement with Modulation Therapeutics, a pharmaceutical company developing therapeutics for the treatment of cancer and liver disease.
Under the agreement, Modulation Therapeutics has applied Pelago Bioscience’s CETSA® technology platform to validate and quantify novel ligands to the Endoplasmic Reticulum Redox Protein ERO1α and ERO2 as described in PCT/US2022/081437 (WO/2023/114761A2) and Johnson et al., Identification of Natural Product Sulfuretin Derivatives as Inhibitors for the Endoplasmic Reticulum Redox Protein ERO1α, ACS Bio Med Chem Au 161–170,2,2 (2022).
Dr. Lori Hazlehurst, Co-Founder and President of Modulation, comments: ’CETSA® is a powerful method to verify cellular target engagement and prioritization of candidate drugs for further development.’
Michael Dabrowski, CEO of Pelago Bioscience comments on the announcement: ’Pelago is excited that Modulation found the CETSA® technology to be a useful method for quantifying drug Target Engagement. We wish Modulation prosperity in their future research in this exciting field.’
Pelago Bioscience welcomes other investigators and those involved in the drug discovery community to engage with us to explore how we can enhance their discovery efforts with the use of our CETSA® technology platform and derived services.
Stockholm, 29 April 2025